Purus Wealth Management LLC Buys 354 Shares of Edwards Lifesciences Co. (NYSE:EW)

Purus Wealth Management LLC raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 10.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,589 shares of the medical research company’s stock after purchasing an additional 354 shares during the quarter. Purus Wealth Management LLC’s holdings in Edwards Lifesciences were worth $266,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in Edwards Lifesciences by 18.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock worth $129,271,000 after acquiring an additional 219,486 shares during the last quarter. Edgestream Partners L.P. bought a new position in shares of Edwards Lifesciences during the second quarter valued at about $438,000. Brighton Jones LLC boosted its holdings in Edwards Lifesciences by 10.0% during the second quarter. Brighton Jones LLC now owns 3,742 shares of the medical research company’s stock worth $346,000 after purchasing an additional 339 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its position in Edwards Lifesciences by 29.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 13,295 shares of the medical research company’s stock worth $1,228,000 after purchasing an additional 3,049 shares in the last quarter. Finally, AE Wealth Management LLC increased its stake in Edwards Lifesciences by 14.8% in the 2nd quarter. AE Wealth Management LLC now owns 4,618 shares of the medical research company’s stock valued at $427,000 after buying an additional 594 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $69.77 on Monday. The stock has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a PEG ratio of 3.77 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $72.06 and a 200 day simple moving average of $71.32. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 earnings per share. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,000 shares of company stock worth $2,195,180. 1.27% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on EW. Truist Financial restated a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Finally, Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $78.48.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.